Benitec Biopharma Inc. 8-K

What Happened

• Benitec Biopharma Inc. announced its financial results and provided an operational update for the fiscal quarter ended March 31, 2026 via a press release dated May 14, 2026. The company filed a Current Report on Form 8-K (Item 2.02) to furnish that press release.

Key Details

• Filing date: May 14, 2026; press release furnished as Exhibit 99.1 to the Form 8-K.
• Reporting period: fiscal quarter ended March 31, 2026 (quarterly results/earnings disclosed in the press release).
• Form 8-K items reported: Item 2.02 (Results of Operations and Financial Condition) and Item 9.01 (Exhibits; includes Exhibit 99.1 and Inline XBRL cover page 104).
• Report signed by Dr. Jerel A. Banks, Chief Executive Officer, on May 14, 2026.

Why It Matters

• The 8-K signals Benitec has released its latest quarterly results and operational update; these disclosures typically contain key metrics investors care about such as revenue, expenses, cash position and program progress.
• Because the Form 8-K furnishes the press release rather than embedding full financial statements, retail investors should read Exhibit 99.1 (the May 14 press release) and watch for the company’s upcoming 10-Q or other filings for complete financial data and footnotes.
• No executive departures, mergers, or other corporate actions were reported in this filing; the primary impact for investors is the new quarterly results and any operational updates described in the press release.